Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
6 Travel Services for Colorful Get-aways: Pick Your Fantasy Escape - 2Find Exemplary Scents: An Extensive Aide
- 3Modern surgery began with saws and iron hands – how amputation transformed the body in the Renaissance
- 4Flourishing in a Cutthroat Work Market: Vocation Methodologies
- 5Turkey key underlying issue as Israel, Greece, Cyprus hold summit
- Trump signs bill allowing whole milk to return to school lunches
- Ski Resorts Universally: A Colder time of year Wonderland Guide
- Taylor Swift changes 2 song lyrics on 'Reputation' on the night of her Eras tour documentary premiere
- Parents who delay baby's first vaccines also likely to skip measles shots
- Which Kind of Pet Makes the Incomparable Buddy?
- Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- Iran Used $2 Billion in Crypto to Run Its Militant Proxies in 2025
- Ways to track down the Right Criminal Legal counselor
- The most effective method to Consummate the Specialty of Handshaking in Business and Group environments
